Home > Boards > US Listed > Biotechs > Puma Biotechnology, Inc. (PBYI)

Perfect short at $10. Up $45k

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Copilotdog  Member Profile
 
Followed By 9
Posts 1,889
Boards Moderated 0
Alias Born 07/05/16
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:11:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:02:09 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/13/2020 12:24:28 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 6:11:57 AM
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 2/7/2020 4:55:00 PM
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results Business Wire - 2/5/2020 4:15:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 12:18:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2020 5:42:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2020 5:38:21 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/3/2020 4:55:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/13/2020 7:32:33 AM
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference Business Wire - 1/13/2020 7:30:00 AM
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 1/9/2020 5:15:00 PM
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Business Wire - 1/7/2020 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 5:15:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 4:48:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 4:33:26 PM
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 12/16/2019 5:55:00 PM
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Pos... Business Wire - 12/13/2019 6:00:00 PM
plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer Business Wire - 12/12/2019 12:30:00 PM
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, ... Business Wire - 12/11/2019 6:03:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/3/2019 4:52:23 PM
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratin... Business Wire - 12/2/2019 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/2/2019 4:06:32 PM
CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries Business Wire - 12/2/2019 11:51:00 AM
Copilotdog   Thursday, 12/05/19 04:00:06 PM
Re: None
Post # of 152 
Perfect short at $10. Up $45k

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist